S48 Efficacy of tezepelumab according to age at asthma onset in NAVIGATOR. (11th November 2022)

• Record Type: Journal Article
• Authors: Brusselle, G; Spahn, JD; Hunter, G; Martin, N; Llanos-Ackert, J-P; Ponnarambil, S
• Is Part Of: Thorax. Volume 77(2022)Supplement 1
• Page Start: A33
• Page End: A33
• Publication Date: 2022-11-11
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thorax-2022-BTSabstracts.54
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Background: Patient age at asthma onset has been shown to affect response to biologic therapies that target type 2 inflammation. Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP). Objective: This pre-specified exploratory analysis assessed the efficacy of tezepelumab in patients with severe, uncontrolled asthma from the phase 3 NAVIGATOR study (NCT03347279 ), grouped by age at asthma onset. Methods: NAVIGATOR was a multicentre, randomized, double-blind, placebo-controlled study. Patients (12–80 years old) „receiving medium- or high-dose inhaled corticosteroids and ≥ 1 additional controller medication, with or without oral corticosteroids, were randomized 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. The annualized asthma exacerbation rate (AAER) was assessed in patients grouped by self-reported age at asthma diagnosis: < 18 (childhood onset), 18–40 (adult onset) and > 40 years old (late onset). Results: Of 1059 patients who received treatment, 399, 358 and 302 patients had childhood-, adult- and late-onset asthma, respectively. In the placebo group, the AAER was lower in patients with childhood-onset asthma (1.72) than in those with adult-onset asthma (2.52) or late-onset asthma (2.11). Tezepelumab reduced the AAER versus placebo by 48% (95% CI: 29–62%), 63% (95% CI: 49–73%) and 56% (95% CI: 37–69%) in patients diagnosed with childhood-, adult- and late-onset asthma, respectively. Conclusion: Tezepelumab reduced exacerbations versus placebo irrespective of age at asthma onset. These data further support the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled asthma. Please refer to page A209 for declarations of interest related to this abstract.